Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today ...

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling ...

Bio-Techne’s 21% return over the past six months has outpaced the S&P 500 by 10.9%, and its stock price has climbed to $62.36 ...

Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...

Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit Establishes a framework to define and propose ...

--Bio-Techne Corporation today reported its financial results for the second quarter ending December 31, 2024. "The Bio-Techne team once again executed at a high level and delivered strong second ...

Shares of Bio-Techne Corp. TECH slid 2.41% to $63.98 Thursday, on what proved to be an all-around mixed trading session for ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...

We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...

Q3 2025 Management View CEO Kim Kelderman highlighted 6% organic revenue growth amidst a challenging macro environment. Key drivers included strength in core reagents, automated analytical solutions, ...